How is Heinz body anemia inherited?

Heinz body anemia follows an autosomal dominant inheritance pattern. This means inheriting just one copy of the altered gene from either parent can cause the condition.

How is Heinz body anemia diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Heinz body anemia?

Information about treatment is currently limited for this condition.

What complications can arise from Heinz body anemia?

Heinz body anemia can lead to complications due to the premature breakdown of red blood cells. This breakdown can cause more severe anemia, which may result in fatigue, weakness, and other health issues. However, specific complications related to this condition are not well-documented, so it's important to monitor symptoms closely.

How does Heinz body anemia affect daily life?

Living with Heinz body anemia may require some adjustments in daily life, especially if symptoms like fatigue occur. Patients might need to take breaks during activities and ensure they maintain a balanced diet to support their health. Regular check-ups with a healthcare provider can help manage any challenges that arise.

What is the life expectancy for someone with Heinz body anemia?

Currently, there is limited information available about the life expectancy of individuals with Heinz body anemia. Since the condition is rare and not well-studied, it is difficult to provide a clear answer. Ongoing research may help clarify the long-term outlook for patients in the future.

Are there any specialists I should see for Heinz body anemia?

It is advisable for individuals with Heinz body anemia to consult with a hematologist, a doctor who specializes in blood disorders. A hematologist can provide guidance on managing the condition and monitor any changes in health. They can also help coordinate care and support for any related symptoms.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Heinz body anemia - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Heinz body anemia

MONDO:0007705

Also known as:Heinz body anemias, alpha-Heinz body anemias

Overview

GeneticsAutosomal dominant · 3 genes (HBA1, HBA2, HBB)

ResearchLimited published research (7 articles)

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include: Heinz bodies, Heinz body anemia, and Nonspherocytic hemolytic anemia.

Organ System	Phenotype Count	Example Features
Blood and immune system	2	Heinz body anemia, Nonspherocytic hemolytic anemia

Genetic Landscape

Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.

HBA1

HBA1 encodes hemoglobin subunit alpha 1 (142 aa). Involved in oxygen transport from the lung to the various peripheral tissues Highest expression in Whole Blood (15,499 TPM) and Spleen (90.4 TPM).

Heinz body anemia is associated with mutations in the HBA1 gene on chromosome 16.

HBA1 is classified as a druggable target with score 8.7.

HBA2

HBA2 encodes hemoglobin subunit alpha 2 (142 aa). Involved in oxygen transport from the lung to the various peripheral tissues Highest expression in Whole Blood (80,864 TPM) and Spleen (944.8 TPM).

Heinz body anemia is associated with mutations in the HBA2 gene on chromosome 16.

HBA2 is classified as a druggable target with score 8.7.

HBB

HBB encodes hemoglobin subunit beta (147 aa). Involved in oxygen transport from the lung to the various peripheral tissues Highest expression in Whole Blood (267,405 TPM) and Spleen (3,152 TPM).

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

Alpha-thalassemia (-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb bart) syndrome (deletion/inactivation of all four alpha globin [-globin] alleles;--/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three -globin alleles;--/-) . Hb Bart syndrome should be suspected in the following:

An at-risk fetus with increased nuchal thickness, thickened placenta, increased cerebral media artery velocity, and increased cardiothoracic ratio on ultrasonography examination at 13-14 weeks' gestation

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Heinz body anemia. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

In 2017, the Thalassemia International Federation updated its Guidelines for the Management of Non-Transfusion-Dependent Thalassemia, including beta-thalassemia (-thalassemia) intermedia, HbH disease, and hemoglobin E/-thalassemia .

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with alpha-thalassemia (-thalassemia), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended. Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome. See .

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

HbH disease

Hematologic evaluation every six to 12 months to determine the steady state levels of Hb
In children, assessment of growth and development every six to 12 months
Monitoring of iron load with annual determination of serum ferritin concentration in individuals who have been transfused, in older individuals, and in those given inappropriate iron supplementation. Since serum ferritin may underestimate the degree of iron overload, a periodic noninvasive quantitative measurement of liver iron concentration by MRI is also recommended .

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for Heinz body anemia.

7 publications have been identified in PubMed for Heinz body anemia. Research spans Case Report / Case Series (43%), Diagnostic / Biomarker (14%), and Review / Meta-Analysis (14%).

Recent Publications

Raviola M (2026). [PMID: 42091220](https://pubmed.ncbi.nlm.nih.gov/42091220/). *Hemoglobin*. [Case Report / Case Series]
Krutish A (2025). [PMID: 40458561](https://pubmed.ncbi.nlm.nih.gov/40458561/). *Frontiers in genetics*. [Case Report / Case Series]
Zhang X (2025). [PMID: 40993672](https://pubmed.ncbi.nlm.nih.gov/40993672/). *Journal of translational medicine*. [Epidemiology / Natural History]
Žoldáková M (2025). [PMID: 39860253](https://pubmed.ncbi.nlm.nih.gov/39860253/). *Molecules (Basel, Switzerland)*. [Review / Meta-Analysis]
Panyasai S (2025). [PMID: 39956031](https://pubmed.ncbi.nlm.nih.gov/39956031/). *Hematology, transfusion and cell therapy*. [Basic Science / Preclinical]

Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:18 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:140700

Orphanet

European rare disease database

Orphanet:178330

Questions for Your Care Team

→Should I pursue genetic testing for the associated genes, and what would the results mean for my family?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Heinz body anemia

Heinz body anemia is a rare blood disorder characterized by the formation of abnormal clumps of hemoglobin in red blood cells, known as Heinz bodies. Although detailed clinical definitions are not available, this condition is linked to changes in red blood cell structure and function. The presence of these Heinz bodies can lead to the premature breaking down of red blood cells, a process that may contribute to anemia. The disorder has been associated with genetic factors, as changes in the HBB, HBA1, and HBA2 genes, which are important for hemoglobin production, are known to be involved. References such as OMIM (OMIM:140700) and Orphanet (Orphanet:178330) list Heinz body anemia as a notable condition. It is also recognized under the synonyms Heinz body anemias, alpha-, and Heinz body anemias, reflecting different aspects or classifications of the disorder.

Information about symptoms is currently limited for this condition.

Heinz body anemia is related to genetic factors, particularly changes in genes such as HBB, HBA1, and HBA2, which play key roles in the production of hemoglobin. However, detailed explanations of the causes, risk factors, and the exact mechanism of the disease are not fully provided in the available sources. Associated genes include HBA1, HBA2, HBB.

← Back to All Diseases

Kisho

Heinz body anemia

Overview

Clinical Presentation

Genetic Landscape

HBA1

HBA2

HBB

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Clinical Guidance

Explore clinical features

Clinical Guidance

Differential Diagnosis

Hydrops Fetalis

Hemoglobin H (HbH) Disease

Treatment of Manifestations

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Heinz body anemia

Overview

Clinical Presentation

Genetic Landscape

HBA1

HBA2

HBB

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Heinz body anemia?

What are the symptoms of Heinz body anemia?

What causes Heinz body anemia?

How is Heinz body anemia inherited?

How is Heinz body anemia diagnosed?

Are there treatments for Heinz body anemia?

What complications can arise from Heinz body anemia?

How does Heinz body anemia affect daily life?

What is the life expectancy for someone with Heinz body anemia?

Are there any specialists I should see for Heinz body anemia?

Clinical Guidance

Explore clinical features

Clinical Guidance

Differential Diagnosis

Hydrops Fetalis

Hemoglobin H (HbH) Disease

Treatment of Manifestations

Clinical Guidance

Therapies Under Investigation

Clinical Trials